Aardvark Evaluates ARD-101 HERO And OLE Data; Next Steps Expected In Q3 2026

Aardvark Therapeutics (AARD), a clinical-stage biopharmaceutical company focused on metabolic diseases, is assessing unblinded Phase 3 HERO and OLE data for ARD-101 in Prader-Willi syndrome (PWS) to determine next steps.